Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04142931
Previous Study | Return to List | Next Study

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04142931
Recruitment Status : Recruiting
First Posted : October 29, 2019
Last Update Posted : March 24, 2021
Sponsor:
Collaborator:
Immunicom Inc. San Diego California, USA
Information provided by (Responsible Party):
Dr. Ronnie Shapira, Sheba Medical Center

Brief Summary:

Sequential immune apheresis plasma volume escalation cohort study of reduction of soluble Tumor Necrosis Factors Receptors 1/2 (sTNFR1/2), with or without Nivolumab, in patients with inoperable or metastatic solid Tumors. This study evaluates Immunicom fs LW-02 device used with Spectra Optia apheresis system, aiming to answer two different study questions:

  • Safety, tolerability and effectiveness of the device.
  • Safety, tolerability and effectiveness of the device, employed as monotherapy, or combined with Nivolumab.

Condition or disease Intervention/treatment Phase
Stage IV Non-small Cell Lung Cancer Stage IV Melanoma Triple Negative Breast Cancer Renal Cell Carcinoma Stage IV Combination Product: ImmunicomAIAC Phase 1

Detailed Description:

This is a pilot, single-center, open-label, sequential immune apheresis plasma volume escalation cohort study of reduction of soluble Tumor Necrosis Factors Receptors 1/2 (sTNFR1/2), with or without Nivolumab, in patients with inoperable or metastatic solid Tumors. This study evaluates Immunicom fs LW-02 device used with Spectra Optia apheresis system, aiming to answer two different study questions:

  • Safety, tolerability and effectiveness of the device.
  • Safety, tolerability and effectiveness of the device, employed as monotherapy, or combined with Nivolumab.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study, Single-Center, Open-Label, Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
Actual Study Start Date : February 24, 2020
Estimated Primary Completion Date : December 30, 2021
Estimated Study Completion Date : December 30, 2022


Arm Intervention/treatment
Active Comparator: filtration of 2X PV
filtration of 2X PV through the ImmunicomAIAC
Combination Product: ImmunicomAIAC
filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2.
Other Name: Nivolumab

Active Comparator: filtration of 2X PV combined with Nivolumab 240mg
filtration of 2X PV through the Immunicom AIAC, and nivolumab 240 mg given every 14 days for 4 times. Nivolumab will be initiated in C2.
Combination Product: ImmunicomAIAC
filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2.
Other Name: Nivolumab




Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events (Safety) of IA therapy with plasma volume escalation (increase from 2X to 3X plasma volume processed): adverse events [ Time Frame: two years ]
    number of patients with adverse events that emerged due to IA

  2. Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) of IA therapy in combination with nivolumab: adverse events [ Time Frame: two years ]
    number of patients with adverse events that emerged due to IA therapy in combination with nivolumab.

  3. Column efficiency [ Time Frame: two years ]
    Changes in sTNFR-1/2 pre and post AIAC column between start and end of every treatment session, and between start and end of every cycle Total capture of sTNF-R1/2 on each column post treatment will be measured using an elution procedure

  4. Column biochemical effectiveness [ Time Frame: two years ]
    The biochemical efficacy will be evaluated throughout the study by measuring the changes of sTNFR-1/2 and TNFα in the plasma in several pre-defined time points - before, during and post every AIAC treatment


Secondary Outcome Measures :
  1. Clinical efficacy: Response Rate (RR) as determined by RECIST v1.1 [ Time Frame: two years ]
    Response Rate (RR) as determined by RECIST v1.1

  2. Circulating biomarkers in plasma cytokines Levels [ Time Frame: two years ]
    changes in plasma cytokines levels: sTNFR-I (pg/ml), sTNFR-II (pg/ml), TNF (pg/ml), pre and post treatment.

  3. Circulating biomarkers in peripheral blood mononuclear cells (PBMC) [ Time Frame: two years ]
    changes in peripheral blood mononuclear cells (PBMC) phenotypes pre and post treatment

  4. Duration of response [ Time Frame: two years ]
    Duration of response (DoR) as determined by RECIST v1.1

  5. Clinical benefit rate [ Time Frame: two years ]
    Clinical benefit rate (CBR) defined as CR plus PR plus stable disease (SD) ≥6 months

  6. Progression Free Survival [ Time Frame: two years ]
    Progression-Free Survival (PFS) as determined by RECIST v1.1

  7. Overall Survival [ Time Frame: two years ]
    Overall Survival (OS)

  8. Clinical efficacy by physician evaluation of ECOG status [ Time Frame: two years ]
    Eastern Cooperative Oncology Group (ECOG) status (score 0-4)

  9. Patient reported outcomes by questionnaire EORTC QLQ-C30 [ Time Frame: two years ]
    Overall quality of life scale: 1 (very poor), 7 (excellent). higher score mean better outcome

  10. Patient reported outcomes by questionnaire EQ-5D- 5L [ Time Frame: two years ]
    patient's health state: 1- 'The best health you can imagine' , 5- 'The worst health you can imagine'. higher score mean worse outcome

  11. Patient reported outcomes by questionaire Hospital Anxiety and Depression Scale (HADS) [ Time Frame: two years ]
    measure anxiety and depression in a general medical population of patients. 0-7 = Normal 8-10 = Borderline abnormal (borderline case) 11-21 = Abnormal (case)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ● Signed informed consent

    • Age ⩾ 18 years
    • Able to comply with study protocol, in the investigator's judgment
    • Histologically confirmed diagnosis of locally advanced unresectable, or metastatic (Stage IV) melanoma, triple negative breast cancer, non-small cell lung cancer, renal cell carcinoma
    • Progressed on at least one standard of care systemic therapy (e.g., chemotherapy or immunotherapy) in advanced/metastatic disease settings prior to inclusion in this study
    • Eastern Cooperative Oncology Group Performance Status of 0 or 1
    • Measurable disease according to RECIST v1.1
    • Life expectancy ⩾ 3 months
    • Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment:

      • ANC ≥ 1.5 x 109/L
      • WBC ≥ 1.5 x 109/L
      • Lymphocyte count ≥ 0.5 x 109/L
      • Platelet count ≥ 100 x 109/L
      • Hemoglobin ≥ 10g/dL (may be achieved with transfusion support)
      • Serum albumin ≥ 3.2mg/dL
      • Total bilirubin ≤ x1.5 ULN
      • AST and ALT ≤ x2.5 ULN (in case of liver metastasis up to x5 ULN)
      • ALP ≤ 2.5 x ULN (in case of liver or bone metastasis up to x5 ULN)
      • Creatinine ≤x2 ULN
      • Serum uric acid ≤ x1.5 ULN
      • Calcium levels within normal range
      • INR≤x1.5 ULN
      • Adequate psychological and physical support structure
    • Female subjects may be enrolled in the trial if they are:

      ○ Of non-childbearing potential which is defined as: i. ⩾ 45 years of age and has not had menses for greater than 1 year ii. Amenorrhea for ⩾ 2 years without a hysterectomy and oophorectomy and FSH value in the postmenopausal range at screening evaluation iii. State post hysterectomy or oophorectomy or tubal ligation. 2. Of childbearing potential who have a negative pregnancy test result within 14 days prior to initiation of study, and agree to remain abstinent or use a contraceptive method with a failure rate of <1% per year during the treatment period (bilateral tubal ligation, male sterilization, hormone releasing intrauterine device and copper intrauterine device; any hormonal contraceptive method must be supplemented with a barrier method)

    • Have provided tissue for biomarker analysis from a newly or recently-obtained biopsy (within 90 days of Study Day 1)
    • Willingness to undergo tumor biopsies of accessible lesions during treatment and at progression for exploratory biomarker analysis

Exclusion Criteria:

  • ● Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 2 weeks of treatment initiation

    • Has received prior chemotherapy, immunotherapy, radioactive or biological cancer therapy within 2 weeks prior to the treatment initiation, or who has not recovered to CTCAE Grade 1 or better from the clinically significant AEs due to cancer therapeutics administered more than 4 weeks prior to treatment initiation, except for stable neurosensory deficits related to chemotherapy and hypothyroidism or type I diabetes due to immunotherapy
    • Is expected to require any other form of systemic or localized antineoplastic therapy while in study
    • Known history of hematologic malignancy or of another primary solid tumor, unless the subject has undergone potentially curative therapy with no evidence of that disease for five years. The time requirement does not apply to the tumor for which the subject is enrolled in the study or subjects that underwent successful definitive resection of basal or squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, in situ breast cancer or other in situ cancers.
    • Have refused standard of care therapy CNS criteria
    • Actively progressing brain metastasis meaning new or enlarging known lesions.
  • Leptomeningeal metastasis
  • Intracranial hemorrhage in the last six months.
  • Patients with CNS metastasis will be eligible if:
  • All lesions treated with radiotherapy or surgery, and are stable for at least 4 weeks prior to initiation of study treatment, and/or
  • Radiographically stable metastasis without local therapy over the last 3 months prior to initiation of study treatment Cardiovascular criteria

    • Unstable angina or new-onset angina within 3 months prior to initiation of study
    • Symptomatic congestive heart failure defined as NYHA Class III or higher
    • Myocardial infarction within 6 months prior to initiation of study
    • Clinically significant hypotension, defined as systolic pressure under 90mmHg
    • Concurrent therapy with ACE inhibitors
    • Significant uncontrolled arrhythmias, with the exception of atrial fibrillation controlled for >30 days prior to initiation of study treatment
    • EF<55% Coagulation criteria
    • History of deep vein thrombosis or pulmonary embolism in the last 6 month.
    • Active or history of hypercoagulability/thrombophilia which is not related to the underlying condition.
    • Fibrinogen serum levels >650mg/dL

Active infection criteria

  • Severe systemic infection within 4 weeks prior to initiation of study, including but not limited to, hospitalization or complications of infection, bacteremia, fungemia, infected stents or indwelling devices etc.
  • Signs and symptoms of infection within 2 weeks prior to initiation of study
  • Positive HIV test
  • Active Hepatitis B infection (chronic or acute), defined as a positive HbsAg test at screening. Past or resolved HBV infection, defined as having a negative hepatitis B surface antigen and a positive total hepatitis B core antibody at screening, are eligible
  • Active Hepatitis C virus infection, defined as having a positive HCV antibody test and a positive HCV RNA test at screening.
  • Treatment with a live attenuated vaccine within 4 weeks prior to initiation of study Other criteria
  • Uncorrectable electrolyte abnormalities
  • Known hypersensitivity to apheresis
  • Current, severe, uncontrolled systemic illness other than cancer, that according to the investigator's judgment should exclude the patient
  • Any psychological, familial, sociological or geographical condition that may mapper compliance with the protocol and follow-up after treatment discontinuation
  • Pregnant or breastfeeding, or intending to become pregnant during the study
  • Known clinically significant liver disease, including alcoholism, cirrhosis or other inherited liver diseases
  • Inability to install central line catheter
  • Treatment with anti TNF agents - infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), and golimumab (Simponi), or etanercept (Enbrel).
  • Active autoimmune disease - known or suspected. Hypothyroidism or hypopituitarism adequately treated with supplemental hormones, type 1 diabetes mellitus or skin disorders (vitiligo, psoriasis, alopecia) not requiring systemic immunosuppression are eligible.
  • Permanent systemic steroid therapy. Steroid treatment equal or less than 10 mg prednisolone (or equivalent) is allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04142931


Contacts
Layout table for location contacts
Contact: Ronnie Shapira, MD 972-3-5308414 ronnie.Shapira@sheba.health.gov.il
Contact: Meital Bar 972-3-5305201 meital.bar@sheba.health.gov.il

Locations
Layout table for location information
Israel
Sheba Medical Center Recruiting
Ramat Gan, Israel, 5262100
Contact: Ronnie Shapira, Dr.       ronnie.shapira@sheba.health.gov.il   
Contact: Meital Bar    972-3-5305201    meital.bar@sheba.health.gov.il   
Principal Investigator: Ronnie Shapira, Dr         
Sponsors and Collaborators
Dr. Ronnie Shapira
Immunicom Inc. San Diego California, USA
Layout table for additonal information
Responsible Party: Dr. Ronnie Shapira, Principal Investigator, Sheba Medical Center
ClinicalTrials.gov Identifier: NCT04142931    
Other Study ID Numbers: SHEBA-19-6136-RS-CTIL
First Posted: October 29, 2019    Key Record Dates
Last Update Posted: March 24, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Triple Negative Breast Neoplasms
Necrosis
Neoplasms by Site
Neoplasms
Neoplasms by Histologic Type
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Kidney Diseases
Urologic Diseases
Breast Neoplasms
Breast Diseases
Skin Diseases
Pathologic Processes
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents